Company intelligence / Profile preview

Ectin Research AB

Mölndal, Västra Götaland, Swedenectinresearch.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Lead drug candidate MFA‑370 was in Phase I/II clinical trials for metastatic urothelial bladder cancer. No published results or further updates available prior to the company's decision to liquidate.

The approach involved a combination therapy aiming to eliminate tumors.

Therapeutic areas: Oncology
Modalities: Small molecules (combination therapy involving two pharmaceuticals)
Industry: Biotech

Drug pipeline

1 asset

MFA-370

Unknown

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed

Beyond the preview

Go deeper on Ectin Research AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ectin Research AB.

Explore the full profile